GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the company will present on its clinical and drug development program for the orphan drug, Trappsol® Cyclo™, at the Niemann-Pick UK (NPUK) 11th Interactive Workshop on Niemann-Pick Diseases and the 27th Annual NPUK Family Conference. The conference brings together patients, families, caregivers, scientists, and health professionals for the purposes of learning about advances in NPC clinical trials and providing opportunities for community learning, sharing and support. The conference will take place virtually from September 25 to 27, 2020.
As it has for the past 5 years, Cyclo Therapeutics also provided an unrestricted grant to the NPUK to assist in support of all conference related activities.
Niemann-Pick Disease Type C (NPC) is a rare and